French MedTech RDS Secures €14m for Wearable Vital Signs Monitor
French medical tech company RDS has secured €14m in a Series A funding round. The investment will support the commercialisation of RDS' innovative MultiSense solution, a wearable patch for continuous remote monitoring of vital signs. The company aims to accelerate growth in Europe and prepare for a US launch in 2028.
RDS' MultiSense patch tracks six key physiological indicators, enabling faster patient discharge and more effective monitoring. Professor Jacques Marescaux, a surgery expert and RDS scientific board member, endorses the technology. The patch has been used in 15 hospitals across France, Belgium, and Germany, though not yet commercially.
The funding will allow RDS to scale its cloud-linked device and expand sales in France, Germany, and other European markets. Led by Bpifrance's SPI fund, the round also saw participation from Critical Path Ventures, MACSF, Capital Grand Est, and others. The global market for vital signs monitoring is projected to reach $15bn this year and grow at a 15% annual rate until 2030, presenting a significant opportunity for RDS.
With €14m in Series A funding, RDS is poised to capitalise on the growing demand for vital signs monitoring solutions. The company's MultiSense patch, backed by medical experts, has shown promise in clinical settings and is set to enter the commercial market. RDS' European expansion and US launch plans are expected to drive growth and solidify its position in the competitive healthcare tech industry.
